Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Sponsor
Waid City Hospital, Zurich
Study ID
NCT07555301
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • IgA Nephropathy (IgAN)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • sparsentan — DRUG
    Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR
  • sparsentan — DRUG
    follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan

Study Details

An observational study tracking the clinical course of patients with IgA nephropathy.

Key Dates

Start date
Jun 1, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with IgA Nephropathie and a therapy with Sparsentan

Primary Outcome Measure

Change of Albuminuria [ Time Frame: 36 months ]

Central Contacts

Related Studies